IA hospital research team from Lawson Health Research Institute has found that expanded dialysis, a new method that removes a broader range of toxins from the body, can improve quality of life in chronic kidney disease patients who struggle with the side effects of traditional dialysis. They shared those results in a press release.
In a clinical trial led by Dr.Chris McIntyre, Nephrologist at London Health Sciences Centre (LHSC) and Scientist at Lawson, dialysis patients at LHSC were administered expanded dialysis through a new dialyzer made by Baxter International Inc.
The dialyzer, called THERANOVA, has precisely-made pores that allow larger sized toxic chemicals to be filtered from the blood while retaining essential molecules such as albumin.
“The chemicals that can now be filtered out can cause inflammation, malnutrition and the buildup of waste,” explains Dr. McIntyre. “With traditional dialysis treatments, we haven’t been as successful at removing those chemicals and some patients experienced significant side effects.”
These larger molecules that the THERANOVA dialyzer is able to filter out are believed to be associated with inflammation, cardiovascular disease and chronic symptoms like fatigue.
This study was conducted for three months with 28 patients. Along with receiving the expanded dialysis treatment, the research participants were monitored through the London Evaluation of Illness (LEVIL) app, developed by Dr. McIntyre with the help of patient input.
“One of our big research challenges is measuring the quality of life on dialysis,” says Dr. McIntyre. “Conventional measures take time and may not be as accurate, so by asking questions through the app every day we were able to get a true idea of how patients were feeling.”
By using the LEVIL app, the team was able to determine that patients that had a poorer quality of life at the start of the study significantly improved in the areas of general wellbeing, energy and sleep after approximately four to eight weeks of expanded dialysis.
Now that the first phase of this study has been completed and published in Kidney Medicine, the next phase will include 60 dialysis patients for up to six months of treatments using the THERANOVA dialyzer.
